Prospectively Assessing Risk for Premature Ovarian Senescence in Young Females: a New Paradigm
Overview
Reproductive Medicine
Affiliations
Background: Approximately 10% of women suffer from premature ovarian senescence (POS), ca. 9% as occult primary ovarian insufficiency (OPOI, also called premature ovarian aging, POA) and ca. 1% as primary ovarian insufficiency (POI, also called premature ovarian failure, POF). In a large majority of cases POS is currently only diagnosed at advanced clinical stages when women present with clinical infertility.
Methods: We here, based on published evidence, suggest a new diagnostic paradigm, which is based on identifying young women at increased risk for POS at much earlier stages.
Results: Risk factors for POS are known from the literature, and can be used to identify a sub-group of young women at increased risk, who then are followed sequentially with serial assessments of functional ovarian reserve (FOR) until a diagnosis of POS is either reached or refuted. At approximately 25% prevalence in general U.S. populations (and somewhat different prevalence rates in more homogenous Asian and African populations), so-called low (CGGn<26) mutations of the fragile X mental retardation 1 (FMR1) gene, likely, represents the most common known risk factor, including history-based risk factors from medical, genetic and family histories.
Conclusions: Women so affirmatively diagnosed with POS at relative young ages, then have the opportunity to reconsider their reproductive planning and/or choose fertility preservation via oocyte or ovarian tissue cryopreservation at ages when such procedures are clinically much more effective and, therefore, also more cost-effective. Appropriate validation studies will have to precede widespread utilization of this paradigm.
Lin W, Wang Y, Zheng L PeerJ. 2024; 12:e17950.
PMID: 39253602 PMC: 11382649. DOI: 10.7717/peerj.17950.
Transcriptomic profile of premature ovarian insufficiency with RNA-sequencing.
Wu J, Feng S, Luo Y, Ning Y, Qiu P, Lin Y Front Cell Dev Biol. 2024; 12:1370772.
PMID: 38655066 PMC: 11035783. DOI: 10.3389/fcell.2024.1370772.
Chang C Int J Mol Sci. 2023; 24(19).
PMID: 37834198 PMC: 10573075. DOI: 10.3390/ijms241914751.
Yefimova M, Ravel C, Rolland A, Bourmeyster N, Jegou B Cells. 2021; 10(6).
PMID: 34207717 PMC: 8229618. DOI: 10.3390/cells10061443.
Henarejos-Castillo I, Aleman A, Martinez-Montoro B, Gracia-Aznarez F, Sebastian-Leon P, Romeu M J Pers Med. 2021; 11(7).
PMID: 34199109 PMC: 8305607. DOI: 10.3390/jpm11070609.